MPZL1

Summary

MPZL1 (myelin protein zero like 1, HGNC:7226) is a protein-coding gene on chromosome 1q24.2, encoding Myelin protein zero-like protein 1 (O95297). Cell surface receptor, which is involved in signal transduction processes.

Predicted to enable structural molecule activity. Predicted to be involved in cell surface receptor protein tyrosine kinase signaling pathway and cell-cell signaling. Located in cell surface and focal adhesion.

Source: NCBI Gene 9019 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 43 total
• MANE Select transcript: NM_003953

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7226
Approved symbol	MPZL1
Name	myelin protein zero like 1
Location	1q24.2
Locus type	gene with protein product
Status	Approved
Aliases	PZR, FLJ21047
Ensembl gene	ENSG00000197965
Ensembl biotype	protein_coding
OMIM	604376
Entrez	9019

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 8 protein_coding, 3 protein_coding_CDS_not_defined, 3 retained_intron, 1 nonsense_mediated_decay

ENST00000359523, ENST00000367853, ENST00000392121, ENST00000403379, ENST00000448405, ENST00000464954, ENST00000465787, ENST00000474729, ENST00000474859, ENST00000487858, ENST00000498279, ENST00000886874, ENST00000917995, ENST00000966246, ENST00000966247

RefSeq mRNA: 3 — MANE Select: NM_003953 NM_001146191, NM_003953, NM_024569

CCDS: CCDS1264, CCDS44273, CCDS53425

Canonical transcript exons

ENST00000359523 — 6 exons

Exon	Start	End
ENSE00001944536	167787820	167791919
ENSE00003469245	167721982	167722242
ENSE00003520577	167773236	167773368
ENSE00003565072	167765583	167765749
ENSE00003633541	167776064	167776166
ENSE00003654118	167772275	167772488

Expression profiles

Bgee: expression breadth ubiquitous, 278 present calls, max score 98.29.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 51.1319 / max 266.0354, expressed in 1818 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
6456	50.8411	1818
6455	0.2908	128

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	98.29	gold quality
gall bladder	UBERON:0002110	97.70	gold quality
cortical plate	UBERON:0005343	97.49	gold quality
rectum	UBERON:0001052	97.13	gold quality
smooth muscle tissue	UBERON:0001135	96.97	gold quality
minor salivary gland	UBERON:0001830	96.92	gold quality
islet of Langerhans	UBERON:0000006	96.87	gold quality
left uterine tube	UBERON:0001303	96.86	gold quality
mucosa of stomach	UBERON:0001199	96.58	gold quality
omental fat pad	UBERON:0010414	96.46	gold quality
peritoneum	UBERON:0002358	96.45	gold quality
colonic epithelium	UBERON:0000397	96.29	gold quality
right coronary artery	UBERON:0001625	96.27	gold quality
ectocervix	UBERON:0012249	96.14	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	96.12	gold quality
ganglionic eminence	UBERON:0004023	96.09	gold quality
saliva-secreting gland	UBERON:0001044	96.04	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.99	gold quality
lower esophagus	UBERON:0013473	95.97	gold quality
endocervix	UBERON:0000458	95.83	gold quality
mouth mucosa	UBERON:0003729	95.83	gold quality
descending thoracic aorta	UBERON:0002345	95.73	gold quality
adipose tissue of abdominal region	UBERON:0007808	95.68	gold quality
tendon of biceps brachii	UBERON:0008188	95.67	gold quality
thoracic aorta	UBERON:0001515	95.64	gold quality
ventricular zone	UBERON:0003053	95.64	gold quality
ascending aorta	UBERON:0001496	95.60	gold quality
esophagus	UBERON:0001043	95.53	gold quality
left coronary artery	UBERON:0001626	95.52	gold quality
calcaneal tendon	UBERON:0003701	95.33	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-6678	no	3.78
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

159 targeting MPZL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-6744-5P	99.93	66.82	748
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-5195-3P	99.92	70.92	1877

Literature-anchored findings (GeneRIF, showing 14)

• PZR is a major receptor of ConA and has an important role in cell signaling via c-Src. Considering the various biological activities of ConA, the study of PZR may have major therapeutic implications (PMID:11751924)
• Characterization of PZR1b, an alternative spliced isoform of PZR. (PMID:12684038)
• the MPZL1/PZR gene may be important in the predisposition to schizophrenia among Han Chinese (PMID:16702974)
• Phosphorylation and localization of PZR in cultured endothelial cells is reported. (PMID:18568953)
• Clinico-electrophysiological features and MRI findings are described in leg musculature from three patients belonging to a CMT2J pedigree due to MPZ Thr124Met mutation. (PMID:19629567)
• MPZL1 is a target gene within the 1q24.1-24.2 amplicon that plays a pivotal role in HCC cell migration and tumor metastasis, and a novel MPZL1/Src/cortactin signaling cascade. (PMID:24296779)
• These data demonstrate that the formation of this MPZL1-PTPN11-GRB2 complex is triggered by the attachment of HER2+ breast cancer cells to fibronectin. (PMID:28912526)
• dimerization of MPZL1 participates in control of its signal transmission in cell adhesion. (PMID:30392906)
• Data indicate that myelin protein zero-like 1 (PZR) may promote the invasion and migration of colorectal cancer (CRC) cells through increasing the phosphorylation of focal adhesion kinase (FAK) and protooncogene SRC (Src). (PMID:30877754)
• High MPZL1 expression is associated with proliferation and metastasis of ovarian cancer. (PMID:31233194)
• The present study showed that the expression and protein levels of MPZL1 were significantly higher in gallbladder carcinoma tissues, especially in patients diagnosed with advanced tumor stages. (PMID:31322261)
• LncRNA TNFRSF10A-AS1 promotes gastric cancer by directly binding to oncogenic MPZL1 and is associated with patient outcome. (PMID:35637954)
• MPZL1 upregulation promotes tumor metastasis and correlates with unfavorable prognosis in non-small cell lung cancer. (PMID:35727197)
• MPZL1 Promotes Lung Adenocarcinoma Progression by Enhancing Tumor Proliferation, Invasion, Migration, and Suppressing Immune Function via Transforming Growth Factor-beta1. (PMID:37183407)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mpzl1l	ENSDARG00000059048
mus_musculus	Mpzl1	ENSMUSG00000026566
rattus_norvegicus	Mpzl1	ENSRNOG00000003248

Paralogs (6): MPZL2 (ENSG00000149573), SCN2B (ENSG00000149575), MPZ (ENSG00000158887), MPZL3 (ENSG00000160588), JAML (ENSG00000160593), SCN4B (ENSG00000177098)

Protein

Protein identifiers

Myelin protein zero-like protein 1 — O95297 (reviewed: O95297)

Alternative names: Protein zero-related

All UniProt accessions (4): A8K5D4, F8WFC4, O95297, Q9UEL6

UniProt curated annotations — full annotation on UniProt →

Function. Cell surface receptor, which is involved in signal transduction processes. Recruits PTPN11/SHP-2 to the cell membrane and is a putative substrate of PTPN11/SHP-2. Is a major receptor for concanavalin-A (ConA) and is involved in cellular signaling induced by ConA, which probably includes Src family tyrosine-protein kinases. Isoform 3 seems to have a dominant negative role; it blocks tyrosine phosphorylation of MPZL1 induced by ConA. Isoform 1, but not isoform 2 and isoform 3, may be involved in regulation of integrin-mediated cell motility.

Subunit / interactions. Interacts with phosphorylated PTPN11/SHP-2.

Subcellular location. Membrane.

Tissue specificity. Widely expressed with highest levels in heart, placenta, kidney and pancreas. Isoform 3 is relatively abundant in hematopoietic tissues and fetal liver. Isoform 1 and isoform 3 are expressed in CD14- PB monocytes and pre-B cell progenitors. Isoform 3 appears to be the major isoform in CD34- promyelocytic and promonocytic cells. During differentiation in monocytic cells, the expression level of isoform 3 decreases and that of isoform 1 increases. Isoform 1 is prominent in stromal cells and, to a lesser extent, in umbilical vein endothelial cells and erythroid progenitors. Isoform 2 is expressed in a erythroid progenitor cell line.

Post-translational modifications. Phosphorylated on tyrosine residues upon stimulation with pervanadate and concanavalin-A (ConA). Phosphorylation at Tyr-241 and Tyr-263 is required for interaction with PTPN11/SHP-2. Dephosphorylated by PTPN11/SHP-2 (in vitro). N-glycosylated. N-glycosylation is required for concanavalin A binding.

Domain organisation. Contains 2 copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in modulation of cellular responses. The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases.

Similarity. Belongs to the myelin P0 protein family.

Isoforms (5)

UniProt ID	Names	Canonical?
O95297-1	1, MPZL1a	yes
O95297-2	2, PZR1a
O95297-3	3, PZR1b
O95297-4	4, MPZL1b
O95297-5	5

RefSeq proteins (3): NP_001139663, NP_003944, NP_078845 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000920	Myelin_P0-rel	Family
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013106	Ig_V-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily

Pfam: PF07686

UniProt features (47 total): strand 13, modified residue 9, splice variant 4, helix 3, glycosylation site 2, topological domain 2, mutagenesis site 2, sequence conflict 2, short sequence motif 2, signal peptide 1, chain 1, disulfide bond 1, transmembrane region 1, turn 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
9MQ5	X-RAY DIFFRACTION	1.7
6IGW	X-RAY DIFFRACTION	1.98
6IGT	X-RAY DIFFRACTION	2.4
6IGO	X-RAY DIFFRACTION	2.75

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95297-F1	77.32	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (9): 204, 206, 208, 210, 219, 221, 241, 260, 263

Disulfide bonds (1): 58–135

Glycosylation sites (2): 50, 130

Mutagenesis-validated functional residues (2):

Position	Phenotype
241	significantly decreases phosphorylation. complete loss of phosphorylation; when associated with f-263.
263	significantly decreases phosphorylation. complete loss of phosphorylation; when associated with f-241.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 209 (showing top): BORCZUK_MALIGNANT_MESOTHELIOMA_UP, MODULE_64, GOZGIT_ESR1_TARGETS_DN, GCAAGGA_MIR502, GOCC_CELL_SURFACE, MORF_RAD51L3, GOBP_CELL_CELL_SIGNALING, PATIL_LIVER_CANCER, WEI_MYCN_TARGETS_WITH_E_BOX, RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP, MORF_CTSB, MORF_IL4, BOYAULT_LIVER_CANCER_SUBCLASS_G1_UP, DODD_NASOPHARYNGEAL_CARCINOMA_UP, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN

GO Biological Process (2): cell surface receptor protein tyrosine kinase signaling pathway (GO:0007169), cell-cell signaling (GO:0007267)

GO Molecular Function (2): structural molecule activity (GO:0005198), protein binding (GO:0005515)

GO Cellular Component (4): plasma membrane (GO:0005886), focal adhesion (GO:0005925), cell surface (GO:0009986), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
enzyme-linked receptor protein signaling pathway	1
cell communication	1
signaling	1
molecular_function	1
binding	1
membrane	1
cell periphery	1
cell-substrate junction	1

Protein interactions and networks

STRING

796 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MPZL1	PMP22	Q01453	955
MPZL1	RNMT	O43148	901
MPZL1	PTPN11	Q06124	880
MPZL1	GJB1	P08034	864
MPZL1	MBP	P02686	859
MPZL1	GDAP1	Q8TB36	841
MPZL1	EGR2	P11161	827
MPZL1	MAG	P20916	821
MPZL1	SIRPA	P78324	818
MPZL1	PRX	Q9BXM0	817
MPZL1	MTMR2	Q13614	685
MPZL1	SOX10	P56693	685
MPZL1	NEFL	P07196	601
MPZL1	PRMT2	P55345	549
MPZL1	PLP1	P04400	522

IntAct

109 interactions, top by confidence:

A	B	Type	Score
MED21	MED19	psi-mi:“MI:0914”(association)	0.880
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
PTPN11	MPZL1	psi-mi:“MI:0914”(association)	0.670
PTPN11	MPZL1	psi-mi:“MI:0915”(physical association)	0.670
TRDN	TMEM223	psi-mi:“MI:0914”(association)	0.640
MPZL1	MFF	psi-mi:“MI:0915”(physical association)	0.560
MPZL1	MPZL1	psi-mi:“MI:0407”(direct interaction)	0.560
IPPK	TMEM223	psi-mi:“MI:0914”(association)	0.530
SLC39A4	TMEM120B	psi-mi:“MI:0914”(association)	0.530
PICK1	ILVBL	psi-mi:“MI:0914”(association)	0.530
TMEM30B	KLRG2	psi-mi:“MI:0914”(association)	0.530
FCGRT	GOLIM4	psi-mi:“MI:0914”(association)	0.530
LGALS3	PODXL	psi-mi:“MI:0914”(association)	0.530
CLGN	NPC1	psi-mi:“MI:0914”(association)	0.530
CCT8L2	ACSL4	psi-mi:“MI:0914”(association)	0.530
CHRNA4	FZD6	psi-mi:“MI:0914”(association)	0.530
ANKH	FAM234B	psi-mi:“MI:0914”(association)	0.530
NRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.480
	RAP1BL	psi-mi:“MI:0915”(physical association)	0.400
NOXRED1	MPZL1	psi-mi:“MI:0915”(physical association)	0.400
TMEM65	MPZL1	psi-mi:“MI:0915”(physical association)	0.400
		psi-mi:“MI:0914”(association)	0.350
	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (195): MPZL1 (Two-hybrid), MPZL1 (Affinity Capture-MS), MPZL1 (Affinity Capture-MS), MPZL1 (Affinity Capture-MS), MPZL1 (Affinity Capture-MS), MPZL1 (Affinity Capture-MS), MPZL1 (Affinity Capture-MS), MPZL1 (Affinity Capture-MS), MPZL1 (Affinity Capture-MS), MPZL1 (Two-hybrid), MPZL1 (Two-hybrid), MPZL1 (Proximity Label-MS), MPZL1 (Affinity Capture-MS), MPZL1 (Affinity Capture-MS), MPZL1 (Affinity Capture-MS)

ESM2 similar proteins: A4FUY1, M0RAS4, O18796, O60939, O75144, O95297, P01857, P01859, P01860, P01861, P07722, P20916, P20917, P51641, P54900, P97546, Q07212, Q08E08, Q14CZ8, Q15223, Q1WIM1, Q1WIM3, Q2KI11, Q32PI9, Q3TEW6, Q56A07, Q640R3, Q6AYP5, Q6AYT8, Q7M729, Q7M730, Q7TNR6, Q864L3, Q8BHK2, Q8HXJ7, Q8IWT1, Q8N126, Q8NFZ8, Q8R464, Q8R5M8

Diamond homologs: A0JM41, A2VD98, A5D7C3, O60487, O60939, O70255, O95297, P06907, P10522, P20938, P25189, P27573, P37301, P54900, Q29RR6, Q32PI9, Q3TEW6, Q3V3F6, Q4KLY3, Q5EAB0, Q5R804, Q6AYT8, Q6UWV2, Q6WEB5, Q7M729, Q7M730, Q86XK7, Q8AVM3, Q8IWT1, Q9D2J4, Q9PWR4, Q08E08, P78310, P97792, Q56A07, Q5R764, Q864L3, Q86YT9, Q8WMV3, Q91664

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
SRC	up-regulates	MPZL1	phosphorylation
PTPN11	down-regulates	MPZL1	dephosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

43 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	30
Likely benign	1
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1452 predictions. Top by Δscore:

Variant	Effect	Δscore
1:167722238:GCTCT:G	donor_gain	1.0000
1:167722239:CTCT:C	donor_gain	1.0000
1:167722241:CT:C	donor_gain	1.0000
1:167722241:CTGT:C	donor_loss	1.0000
1:167722242:TGT:T	donor_loss	1.0000
1:167722243:G:C	donor_loss	1.0000
1:167722243:G:GG	donor_gain	1.0000
1:167722244:T:A	donor_loss	1.0000
1:167765581:A:AG	acceptor_gain	1.0000
1:167765581:AGT:A	acceptor_gain	1.0000
1:167765582:G:GA	acceptor_gain	1.0000
1:167765582:GT:G	acceptor_gain	1.0000
1:167765582:GTG:G	acceptor_gain	1.0000
1:167765582:GTGAC:G	acceptor_gain	1.0000
1:167765746:GTCG:G	donor_gain	1.0000
1:167765747:TCGG:T	donor_loss	1.0000
1:167765748:CGGT:C	donor_loss	1.0000
1:167765750:G:GG	donor_gain	1.0000
1:167765750:GTAA:G	donor_loss	1.0000
1:167765751:T:A	donor_loss	1.0000
1:167772273:A:AG	acceptor_gain	1.0000
1:167772274:G:GA	acceptor_gain	1.0000
1:167772469:GCTC:G	donor_gain	1.0000
1:167772484:AAAAG:A	donor_loss	1.0000
1:167772486:AAGG:A	donor_loss	1.0000
1:167772487:AGGTA:A	donor_loss	1.0000
1:167772488:GGTA:G	donor_loss	1.0000
1:167772490:T:G	donor_loss	1.0000
1:167773235:GA:G	acceptor_gain	1.0000
1:167773235:GAGA:G	acceptor_gain	1.0000

AlphaMissense

1735 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:167772419:T:A	C135S	0.998
1:167772420:G:A	C135Y	0.998
1:167772420:G:C	C135S	0.998
1:167765711:T:A	W74R	0.997
1:167765711:T:C	W74R	0.997
1:167772413:T:G	Y133D	0.997
1:167772419:T:C	C135R	0.997
1:167765663:T:A	C58S	0.996
1:167765664:G:C	C58S	0.996
1:167765713:G:C	W74C	0.996
1:167765713:G:T	W74C	0.996
1:167772421:T:G	C135W	0.996
1:167772426:T:A	V137D	0.996
1:167765664:G:A	C58Y	0.995
1:167765665:C:G	C58W	0.994
1:167772420:G:T	C135F	0.994
1:167765663:T:C	C58R	0.993
1:167772371:T:C	S119P	0.993
1:167772408:G:T	G131V	0.993
1:167772343:G:C	W109C	0.992
1:167772343:G:T	W109C	0.992
1:167772375:T:A	I120N	0.992
1:167772407:G:T	G131C	0.992
1:167765664:G:T	C58F	0.991
1:167765670:T:G	F60C	0.991
1:167765706:T:A	V72D	0.991
1:167772324:T:G	F103C	0.991
1:167772408:G:A	G131D	0.991
1:167772477:T:A	V154D	0.991
1:167765717:T:C	F76L	0.990

dbSNP variants (sampled 300 via entrez): RS1000022546 (1:167784814 A>G), RS1000080603 (1:167762698 G>A), RS1000143127 (1:167738752 C>T), RS1000154350 (1:167762437 C>T), RS1000176964 (1:167736880 A>G), RS1000189272 (1:167789473 G>A), RS1000226742 (1:167780258 T>C), RS1000230751 (1:167736624 C>T), RS1000266350 (1:167726347 A>C), RS1000314833 (1:167744577 G>C,T), RS1000554627 (1:167737312 C>G), RS1000601190 (1:167724306 G>A), RS1000656666 (1:167743223 T>C), RS1000703672 (1:167731378 A>G), RS1000707829 (1:167772987 T>C)

Disease associations

OMIM: gene MIM:604376 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001658_4	Alzheimer’s disease (late onset)	1.000000e-06
GCST003265_214	Post bronchodilator FEV1/FVC ratio in COPD	5.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004713	FEV/FVC ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

65 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	5
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	2
Benzo(a)pyrene	decreases methylation, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
FR900359	affects phosphorylation	1
bisphenol F	increases expression, affects cotreatment	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
ascorbate-2-phosphate	affects binding, affects cotreatment, increases expression	1
trichostatin A	increases expression	1
diethyl maleate	decreases expression	1
sulforaphane	decreases expression	1
cobaltous chloride	increases expression	1
nickel sulfate	decreases expression	1
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid	affects cotreatment, increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
Chir 99021	affects binding, affects cotreatment, increases expression	1
nutlin 3	affects cotreatment, increases secretion	1
ICG 001	decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
XAV939	affects cotreatment, increases expression, affects binding	1
LDN 193189	increases expression, affects cotreatment	1
3-(4-pyridyl)-1H-indole	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Acetaminophen	increases expression	1
Adenine	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1XI	Abcam HeLa MPZL1 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.